Q2 2026 13F · SEC CIK 2102314

Jones Hill Capital LP

Hedge fundFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $470.4M
Reported positions: 29
Holdings vs S&P 500, 3 yrs: —
Assets under management: $642.4M

Jones Hill Capital LP is a hedge fund that reported 29 positions worth $470.4M in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Biomarin Pharmaceutical Inc (BMRN, 17.4%), Gilead Sciences Inc (GILD, 9.2%), Arcutis Biotherapeutics Inc (ARQT, 6.1%).

Jones Hill Capital LP holdings all 29 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Jones Hill Capital LP 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
BMRNBiomarin Pharmaceutical Inc	17.4%	15.4%	1,431,590	+12.9%	$81.9M
GILDGilead Sciences Inc	9.2%	New	343,043	—	$43.3M
ARQTArcutis Biotherapeutics Inc	6.1%	New	1,089,701	—	$28.6M
MDGLMadrigal Pharmaceuticals Inc	6.0%	New	52,545	—	$28.2M
BCAXBicara Therapeutics Inc	5.6%	5.4%	892,621	-29.2%	$26.5M
RLMDRelmada Therapeutics Inc	5.4%	0.5%	3,655,075	+966.4%	$25.3M
TRVITrevi Therapeutics Inc	5.3%	0.9%	1,339,212	+261.8%	$25.0M
PHVSPharvaris N V	5.0%	1.0%	677,879	+305.9%	$23.4M
XENEXenon Pharmaceuticals Inc	4.7%	New	367,900	—	$22.2M
ANIPAni Pharmaceuticals Inc	4.1%	5.3%	233,808	-26.6%	$19.4M
IMCRImmunocore Hldgs PLC	3.5%	New	512,856	—	$16.3M
AMLXAmylyx Pharmaceuticals Inc	3.4%	4.8%	894,058	-44.1%	$16.1M
INSMInsmed Inc	2.8%	New	122,375	—	$13.0M
NUVLNuvalent Inc	2.6%	6.6%	98,442	-67.3%	$12.2M
CAPRCapricor Therapeutics Inc	2.2%	5.9%	420,751	-53.7%	$10.1M
ACRSAclaris Therapeutics Inc	2.0%	New	1,759,492	—	$9.3M
4525EP200Immunic Inc	1.8%	New	539,814	—	$8.3M
ORICOric Pharmaceuticals Inc	1.7%	New	747,313	—	$8.1M
TNXPTonix Pharmaceuticals Hldg C	1.7%	1.3%	625,428	+38.3%	$8.0M
SNDXSyndax Pharmaceuticals Inc	1.6%	New	340,000	—	$7.4M
OLMAOlema Pharmaceuticals Inc	1.5%	New	574,166	—	$7.2M
VIRVir Biotechnology Inc	1.4%	2.3%	659,213	-45.0%	$6.7M
CRBPCorbus Pharmaceuticals Hldgs	1.3%	New	653,572	—	$6.1M
DNTHDianthus Therapeutics Inc	1.2%	New	57,100	—	$5.6M
VRTXVertex Pharmaceuticals Inc	1.2%	10.4%	11,123	-89.8%	$5.5M
ELVNEnliven Therapeutics Inc	0.5%	5.0%	49,850	-91.6%	$2.5M
GPCRStructure Therapeutics F Unspo	0.5%	1.0%	40,567	-59.7%	$2.2M
PHATPhathom Pharmaceuticals Inc Com	0.4%	New	161,486	—	$1.8M
ACHVAchieve Life Science Inc	0.0%	New	26,760	—	$175K

What Jones Hill Capital LP bought and sold in Q2 2026, against Q1 2026.

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: —
3 years: —
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$470.4M	29
Q1 2026	$466.5M	26

Questions about Jones Hill Capital LP's portfolio

What stocks does Jones Hill Capital LP own?

Jones Hill Capital LP's latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 29 positions worth $470.4M. The largest are Biomarin Pharmaceutical Inc (BMRN) at 17.4%, Gilead Sciences Inc (GILD) at 9.2%, Arcutis Biotherapeutics Inc (ARQT) at 6.1%, Madrigal Pharmaceuticals Inc (MDGL) at 6.0% and Bicara Therapeutics Inc (BCAX) at 5.6%.

What did Jones Hill Capital LP buy last quarter?

In Q2 2026, Jones Hill Capital LP added a new position in Gilead Sciences Inc (GILD), a new position in Arcutis Biotherapeutics Inc (ARQT), a new position in Madrigal Pharmaceuticals Inc (MDGL), a new position in Xenon Pharmaceuticals Inc (XENE), a new position in Immunocore Hldgs PLC (IMCR), Relmada Therapeutics Inc (RLMD) (+966.4% shares), Pharvaris N V (PHVS) (+305.9% shares) and Trevi Therapeutics Inc (TRVI) (+261.8% shares), compared with its Q1 2026 filing.

What did Jones Hill Capital LP sell last quarter?

In Q2 2026, Jones Hill Capital LP sold all of Vaxcyte Inc (PCVX), sold all of Terns Pharmaceuticals Inc (TERN), sold all of Ultragenyx Pharmaceutical in (RARE), sold all of Argenx SE (ARGNF), sold all of Fulcrum Therapeutics Inc (FULC), Enliven Therapeutics Inc (ELVN) (-91.6% shares), Vertex Pharmaceuticals Inc (VRTX) (-89.8% shares) and Nuvalent Inc (NUVL) (-67.3% shares), compared with its Q1 2026 filing.

When is Jones Hill Capital LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Jones Hill Capital LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Jones Hill Capital LP manage?

Jones Hill Capital LP reported $642.4M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $470.4M.